Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
7 hedge funds and large institutions have $768K invested in Celyad Oncology SA American Depositary Shares in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
49% less capital invested
Capital invested by funds: $1.49M → $768K (-$725K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$14.6K |
| 2 |
JP Morgan Chase
New York
|
+$13.1K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$8.22K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$6.32K |
| 5 |
Morgan Stanley
New York
|
+$1.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$419K |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$67K |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$60K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ECM
1
Endurant Capital Management
San Mateo,
California
| $596K | -$67K | -15,311 | -10% |
|
|
2
Morgan Stanley
New York
| $102K | +$1.31K | +300 | +1% |
|
|
3
Wells Fargo
San Francisco,
California
| $32K | +$6.32K | +1,445 | +23% |
|
|
4
UBS Group
Zurich,
Switzerland
| $18K | +$14.6K | +3,335 | +316% |
|
|
5
JP Morgan Chase
New York
| $12K | +$13.1K | +3,000 | New |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| $8K | +$8.22K | +1,880 | New |
|
|
7
Victory Capital Management
San Antonio,
Texas
| – | -$419K | -79,902 | Closed |
|
|
OMC
8
Old Mission Capital
Chicago,
Illinois
| – | -$60K | -11,323 | Closed |
|
CYAD Hedge Fund Activity: Q3 2021 in Review
7 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q3 2021, worth a combined $768K — down 49% from $1.49M a quarter earlier.
Fund positioning in CYAD was balanced in Q3 2021: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $14.6K. The largest seller was Victory Capital Management, exiting entirely with an estimated $419K sold.
- 7 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $768K of Celyad Oncology SA American Depositary Shares stock for Q3 2021, down 49% quarter-over-quarter.
- 2 funds opened new Celyad Oncology SA American Depositary Shares positions in Q3 2021 and 2 closed out, a net change of 0 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q3 2021 was UBS Group, an estimated $14.6K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q3 2021 was Victory Capital Management, an estimated $419K sold.
Based on aggregated 13F filings for Q3 2021.